Entzündliche Muskelkrankheiten

Anders HJ, Wanders A, Rihl M, Kruger K (1999) Myocardial fibrosis in polymyositis. J Rheumatol 26: 1840–1842

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344–347

Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC (1999) Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 42: 899–909

Christopher-Stine L, Plotz PH (2004) Myositis: an update on pathogenesis. Curr Opin Rheumatol 16: 700–706

Dalakas MC (2002) Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 28: 779–798

Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51 (Suppl): S37–45

Dalakas MC (2004) Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 17: 561–567

Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362: 971–982

De Vita S, Fossaluzza V (1992) Treatment of idiopathic inflammatory myopathies with cyclophosphamide pulses: clinical experience and a review of the literature. Acta Neurol Belg 92: 215–227

Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz P (1991) Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 18: 1693–1700

Genth E (1998) Autoantikörper bei Dermato- und Polymyositiden. In: Conrad K (Hrsg) Autoantikörper. Pabst Science Publishers, Lengerich Berlin Düsseldorf Riga

Genth E, Kaufmann S, Mierau R (1993) Das Anti-(Aminoacyl-tRNA-)Synthetase-Syndrom (Jo-1-Syndrom). Ein eigenständiges Autoantikörper-assoziiertes Krankheitsbild mit Myositis, fibrosierender Alveolitis und Polyarthritis. Akt Rheumatol 7: 113–119

Hill CL, Zhang Y, Sigurgeirsson B et al. (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357: 96–100

Joffe MM, Love LA, Leff RL et al. (1993) Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 94: 379–387

Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH (1993) The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 72: 225–235

Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70: 360–374

Mastaglia FL, Phillips BA (2002) Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 28: 723–741

Mastaglia FL, Zilko PJ (2003) Inflammatory myopathies: how to treat the difficult cases. J Clin Neurosci 10: 99–101

Mozaffar T, Pestronk A (2000) Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 68: 472–478

Plotz PH, Rider LG, Targoff IN, Raben N, O’Hanlon TP, Miller FW (1995) NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 122: 715–724

Schnabel A, Reuter M, Biederer J, Richter C, Gross WL (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32: 273–284

Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326: 363–367

Sontheimer RD (2002) Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 20: 387–408

Spiera R, Kagen L (1998) Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opin Rheumatol 10: 556–561

Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002) Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41: 22–26

Targoff IN (1992) Autoantibodies in polymyositis. Rheum Dis Clin North Am 18: 455–82

Targoff IN, Johnson AE, Miller FW (1990) Antibody to signal recognition particle in polymyositis Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33: 1361–1370

Yamanishi Y, Maeda H, Katayama S, Ishioka S, Yamakido M (1996) Scleroderma-polymyositis overlap syndrome associated with anti-Ku antibody and rimmed vacuole formation. J Rheumatol 23: 1991–1994

Yazici Y, Kagen LJ (2002) Cardiac involvement in myositis. Curr Opin Rheumatol 14: 663–665